-
1 Comment
Mabion S.A. is currently in a long term uptrend where the price is trading 53.2% above its 200 day moving average.
Its net income has increased by 45.5% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 10.2% to $-29M since the same quarter in the previous year.
Based on the above factors, Mabion S.A. gets an overall score of 3/5.
| Exchange | WAR |
|---|---|
| CurrencyCode | PLN |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | PLMBION00016 |
| Market Cap | 163M |
|---|---|
| Beta | 0.55 |
| PE Ratio | 15.97 |
| Target Price | 8.1667 |
| Dividend Yield | None |
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MAB.WAR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
